Fulcrum Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates as the company pivoted to a strategic wind-down. GAAP EPS was -$0.34 vs. -$0.22 expected, primarily due to $9.4M in restructuring and impairment charges following the discontinuation of the lead pociredir program. While the top-line revenue of $0 was in-line with expectations for this clinical-stage firm, operating losses widened to $29.3M, significantly exceeding the anticipated $19.5M loss. The company ended the quarter with $318.8M in liquidity and an 85% workforce reduction, shifting focus entirely to a comprehensive review of strategic alternatives.